Safety and Efficacy Study of Repeated Doses of DX-88 (Ecallantide) to Treat Attacks of Hereditary Angioedema (HAE)
Status:
Completed
Trial end date:
2010-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of repeated doses of
ecallantide in the treatment of acute attacks of hereditary angioedema and to allow HAE
patients continued access to ecallantide. In addition, patients enrolled in DX-88/20 (EDEMA4)
trial will be followed up and treated for subsequent attacks in this trial.